ACRV insider transaction filings

Acrivon Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen ACRV transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-204Gamelin Erick — Chief Development OfficerSale (S): 400 @ $2.01EDGAR
2026-08-204Miller Mary — Chief Legal OfficerSale (S): 185 @ $2.01EDGAR
2026-08-204Peterson Katharine — Chief Accounting OfficerSale (S): 101 @ $2.01EDGAR
2026-08-204Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Sale (S): 1,229 @ $2.01 · Sale (S): 484 @ $2.01EDGAR
2026-08-204Devroe Eric — Chief Operating OfficerSale (S): 604 @ $2.01EDGAR
2026-08-064Levy Adam D. — Chief Financial OfficerSale (S): 1,142 @ $1.57EDGAR
2026-07-234Miller Mary — Chief Legal OfficerSale (S): 573 @ $1.76EDGAR
2026-06-224Palani Santhosh — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224DiRocco Derek — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224Shacham Sharon — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224BAUM CHARLES M — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224TOMSICEK MICHAEL JOHN — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund II, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Grant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 20,275 (derivative) @ $0EDGAR
2026-05-264Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Tax withholding (F): 13,729 @ $1.79EDGAR
2026-05-204Palani Santhosh — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-204DiRocco Derek — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-204Peterson Katharine — Chief Accounting OfficerGrant/award (A): 14,227 @ $0EDGAR
2026-05-204Miller Mary — Chief Legal OfficerGrant/award (A): 49,830 @ $0EDGAR
2026-05-204Levy Adam D. — Chief Financial OfficerGrant/award (A): 46,167 @ $0EDGAR
2026-05-204Gamelin Erick — Chief Development OfficerGrant/award (A): 38,584 @ $0EDGAR
2026-05-204Devroe Eric — Chief Operating OfficerGrant/award (A): 72,981 @ $0EDGAR
2026-05-204Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Grant/award (A): 180,095 @ $0 · Grant/award (A): 72,706 @ $0EDGAR
2026-05-204Shacham Sharon — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-204Mirza Mansoor Raza — Chief Medical OfficerGrant/award (A): 38,817 @ $0EDGAR
2026-05-204BAUM CHARLES M — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-204TOMSICEK MICHAEL JOHN — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-204RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund II, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Grant/award (A): 9,366 @ $0EDGAR
2026-05-204Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 9,366 @ $0EDGAR
2026-05-184Peterson Katharine — Chief Accounting OfficerTax withholding (F): 99 @ $1.92EDGAR
2026-05-184Miller Mary — Chief Legal OfficerTax withholding (F): 184 @ $1.92EDGAR
2026-05-184Gamelin Erick — Chief Development OfficerTax withholding (F): 404 @ $1.92EDGAR
2026-05-184Devroe Eric — Chief Operating OfficerTax withholding (F): 613 @ $1.92EDGAR
2026-05-184Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Tax withholding (F): 1,253 @ $1.92 · Tax withholding (F): 490 @ $1.92EDGAR
2026-04-234RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund II, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Grant/award (A): 3,888,888 @ $1.80EDGAR
2026-04-214Miller Mary — Chief Legal OfficerTax withholding (F): 558 @ $1.78EDGAR
2026-03-034Peterson Katharine — Chief Accounting OfficerGrant/award (A): 31,900 (derivative) @ $0EDGAR
2026-03-034Miller Mary — Chief Legal OfficerGrant/award (A): 129,760 (derivative) @ $0EDGAR
2026-03-034Levy Adam D. — Chief Financial OfficerGrant/award (A): 132,925 (derivative) @ $0EDGAR
2026-03-034Gamelin Erick — Chief Development OfficerGrant/award (A): 94,946 (derivative) @ $0EDGAR
2026-03-034Devroe Eric — Chief Operating OfficerGrant/award (A): 186,728 (derivative) @ $0EDGAR
2026-03-034Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Grant/award (A): 417,210 (derivative) @ $0 · Grant/award (A): 185,495 (derivative) @ $0EDGAR
2026-03-034Mirza Mansoor Raza — Chief Medical OfficerGrant/award (A): 174,068 (derivative) @ $0EDGAR
2026-02-244Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Tax withholding (F): 14,265 @ $1.53EDGAR
2026-02-184Peterson Katharine — Chief Accounting OfficerTax withholding (F): 116 @ $1.63EDGAR
2026-02-184Miller Mary — Chief Legal OfficerTax withholding (F): 217 @ $1.63EDGAR
2026-02-184Gamelin Erick — Chief Development OfficerTax withholding (F): 471 @ $1.63EDGAR
2026-02-184Devroe Eric — Chief Operating OfficerTax withholding (F): 723 @ $1.63EDGAR
2026-02-184Blume-Jensen Peter — President and CEO, Director
Masson Kristina — EVP - Business Operations, Director
Tax withholding (F): 1,302 @ $1.63 · Tax withholding (F): 579 @ $1.63EDGAR
2026-01-214Miller Mary — Chief Legal OfficerTax withholding (F): 659 @ $1.98EDGAR

Recent 8-K events — Acrivon Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-178-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-198-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-028-K1.02 — Termination of a Material Definitive AgreementEDGAR
2026-02-278-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-088-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-088-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-09-058-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ACRV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →